Logo Image
News
Media
Peer ExchangeCase-Based Psych PerspectivesClinical Case CollectiveClinical Forum InsightsInsightsPeers & PerspectivesPodcastsShortsSlideshowsVideos
Conferences
Conference CoverageConference Listing
Publication
Psychiatric Times
More
Job Board
CME/CE
Partners
Editorial
Resources
Between the LinesExpert PerspectivesClinical ConsultClinical ScalesInteractive ToolsLive EventsPartner PerspectivesQ&AQuizzesSeriesSpecial ReportsSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Publication
  • Job Board
  • CME/CE
  • Partners
  • Editorial
  • Resources
  • Subscribe
  • ADHD
  • Addiction & Substance Use
    • Behavioral Addictions
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Amphetamine Related Disorders
    • Substance Use Disorder
  • Alzheimer Disease & Dementia
  • Anxiety Disorders
    • Panic Disorder
  • Cannabis
  • Case Discussions
  • Comorbidity
  • Consultation-Liaison Psychiatry
    • COVID-19
  • Cultural Psychiatry
  • Drug Watch
  • Eating Disorders
  • Emergency Psychiatry
  • Ethics
  • Forensic Psychiatry
    • Munchausen Syndrome
    • Sexual Offenses
  • Integrative Psychiatry
  • Life Cycle Psychiatry
    • Postpartum Disorders
    • Geriatric Psychiatry
    • Child & Adolescent Psychiatry
  • Mental Health Awareness Month
  • Mood Disorders
    • Treatment-Resistant Depression
    • Major Depressive Disorder
    • Bipolar Disorder
  • Neuromodulation
  • Neuropsychiatry
    • Cognition
    • Dementia
    • Autism
  • Obsessive-Compulsive Disorders
  • PTSD, Trauma & Stress Disorders
    • Disaster Psychiatry
    • Trauma And Violence
    • Traumatic Stress Disorders
  • Personality Disorders
    • Compulsive Personality Disorder
    • Dependent Personality Disorder
    • Dissociative Identity Disorder
    • Histrionic Personality Disorder
    • Schizoid Personality Disorder
    • Antisocial Personality Disorder
    • Borderline Personality
  • Psychedelics & Cannabis
  • Psychiatry & Society
    • Diversity, Equity, Inclusion
    • Climate Change
    • Media & Psychiatry
  • Psychopharmacology
  • Psychosomatics
    • Delirium
    • Metabolic Disorders
    • Somatoform Disorder
  • Psychotherapy
    • Cognitive Behavioral Therapy
  • Schizophrenia/Psychosis
    • Paranoid Schizophrenia
    • Psychotic Affective Disorders
    • Schizoaffective
    • Schizophrenia Psychotic Features
    • Schizotypal Personality Disorder
    • Catatonic Schizophrenia
  • Sleep-Wake Disorders
    • Narcolepsy
    • Nocturnal Paroxysmal Dystonia
    • Sleep Deprivation
    • Sleep Wake Transition
    • Circadian Rhythm Sleep Disorders
  • Special Populations
    • Sports Psychiatry
    • Pervasive Developmental Disorder
    • LGBTQ+
    • Gender Issues
    • Military Mental Health
  • Suicide
  • Tardive Dyskinesia
  • Technology & Psychiatry
    • Digital Therapeutics
    • Artificial Intelligence
Spotlight -
Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|
Major Depressive Disorder
Advertisement

Betsy D. Kennard, PsyD, ABPP

Advertisement

Articles by Betsy D. Kennard, PsyD, ABPP

Pediatric Major Depressive Disorder: Questions to Consider

ByBetsy D. Kennard, PsyD, ABPP,Aleksandra A. Foxwell, PhD,Taryn L. Mayes, MS,Graham J. Emslie, MD
November 16th 2012

What are the options for treating major depressive disorder in children and adolescents? This case offers readers a chance to give their feedback and to interact with the authors, who will present teaching points based on your comments.

Advertisement

Latest Updated Articles

  • Pediatric Major Depressive Disorder: Questions to Consider
    Pediatric Major Depressive Disorder: Questions to Consider

    November 16th 2012



Advertisement
Advertisement

Trending on Psychiatric Times

1

The Top 7 Atypical Psychedelics: A Brief Clinical Guide

2

Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD

3

Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder

4

FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder

5

New Preliminary Positive Data From Open-Label Extension of Phase 3 Study: Fasedienol for the Acute Treatment of Social Anxiety Disorder

  • About
  • Advertise
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us